Potassium sodium hydrogen citrate
Sibnayal (potassium sodium hydrogen citrate) is an unknown pharmaceutical. Potassium sodium hydrogen citrate was first approved as Sibnayal on 2021-04-30. It has been approved in Europe to treat renal tubular acidosis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
993 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | 2 | 10 | 5 | 6 | 15 | 36 |
| Dentin sensitivity | D003807 | — | — | 4 | 1 | 3 | 2 | 14 | 23 |
| Tooth discoloration | D014075 | — | K03.6 | — | — | — | 4 | 19 | 23 |
| Healthy volunteers/patients | — | — | — | 8 | 2 | — | 2 | 8 | 19 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | 1 | 2 | 15 | 19 |
| Infections | D007239 | EFO_0000544 | — | 1 | 4 | 5 | 1 | 4 | 14 |
| Tooth bleaching | D014073 | — | — | 1 | — | 2 | 3 | 8 | 14 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | 1 | — | 1 | 2 | 8 | 12 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 2 | — | — | 1 | 8 | 11 |
| Lactose intolerance | D007787 | — | E73 | — | — | 1 | 1 | 9 | 11 |
Show 67 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 27 | 51 | 10 | — | 1 | 78 |
| Recurrence | D012008 | — | — | 13 | 37 | 3 | — | 3 | 50 |
| Non-small-cell lung carcinoma | D002289 | — | — | 14 | 25 | 8 | — | — | 39 |
| Lung neoplasms | D008175 | — | C34.90 | 12 | 20 | 7 | — | 3 | 36 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 10 | 23 | 7 | — | — | 36 |
| Neoplasms | D009369 | — | C80 | 13 | 14 | 4 | — | 6 | 35 |
| Adenocarcinoma | D000230 | — | — | 11 | 24 | 5 | — | — | 35 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 11 | 17 | 6 | — | 2 | 32 |
| Fallopian tube neoplasms | D005185 | — | — | 8 | 20 | 6 | — | — | 30 |
| Squamous cell carcinoma | D002294 | — | — | 9 | 11 | 6 | — | 2 | 23 |
Show 125 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 7 | 9 | — | — | 5 | 21 |
| Lymphoma | D008223 | — | C85.9 | 6 | 16 | — | — | — | 18 |
| Melanoma | D008545 | — | — | 6 | 11 | — | — | 1 | 16 |
| Syndrome | D013577 | — | — | 3 | 3 | — | — | 10 | 14 |
| Inflammation | D007249 | MP_0001845 | — | 3 | 2 | — | — | 6 | 11 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 6 | 5 | — | — | — | 9 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 4 | 2 | — | — | 3 | 9 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 5 | — | — | 4 | 9 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 5 | 7 | — | — | — | 9 |
| B-cell lymphoma | D016393 | — | — | 5 | 6 | — | — | — | 9 |
Show 186 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peri-implantitis | D057873 | EFO_1001390 | — | 1 | — | — | — | 6 | 7 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 2 | — | — | — | 5 | 7 |
| Fatigue | D005221 | — | R53.83 | 1 | — | — | — | 6 | 7 |
| Vasodilation | D014664 | — | — | 3 | — | — | — | 3 | 6 |
| Wound healing | D014945 | GO_0042060 | — | 1 | — | — | — | 5 | 6 |
| Vasoconstriction | D014661 | — | — | 3 | — | — | — | 2 | 5 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | 1 | — | — | — | 3 | 4 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | 2 | — | — | — | 1 | 3 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 2 | — | — | — | 1 | 3 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | 2 | 3 |
Show 67 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Refractive errors | D012030 | HP_0000483 | H52.7 | — | — | — | — | 25 | 25 |
| Myopia | D009216 | EFO_0003927 | H52.1 | — | — | — | — | 12 | 12 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 9 | 9 |
| Presbyopia | D011305 | — | H52.4 | — | — | — | — | 7 | 7 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | — | — | — | 7 | 7 |
| Fistula | D005402 | — | — | — | — | — | — | 7 | 7 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | — | 7 | 7 |
| Astigmatism | D001251 | EFO_0004222 | H52.2 | — | — | — | — | 7 | 7 |
| Hyperopia | D006956 | EFO_0006310 | H52.0 | — | — | — | — | 5 | 5 |
| Rectal fistula | D012003 | — | K60.3 | — | — | — | — | 5 | 5 |
Show 219 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Potassium sodium hydrogen citrate |
| INN | — |
| Description | Sibnayal (potassium sodium hydrogen citrate) is an unknown pharmaceutical. Potassium sodium hydrogen citrate was first approved as Sibnayal on 2021-04-30. It has been approved in Europe to treat renal tubular acidosis. |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594488 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,165 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use